Ajanta Pharma Ltd. News, Corporate filings and Earnings/Conference Calls

Name: Latest research reports of Ajanta Pharma Ltd. authored by ICICI Direct and published by - Trendlyne research reports.
Item: Ajanta Pharma Ltd.
Rating: 5
Author: ICICI Direct

Keep track of all breaking news and updates on Ajanta Pharma Ltd. from all sources in a single place.

Load latest

Ajanta Pharma Ltd.

31 Jul 2024

2676.40

1.57%

Company Update

AJANTA PHARMA LTD. - 532331 - Announcement under Regulation 30 (LODR)-Newspaper Publication

BSE India

PFA herewith results published in newspapers.

pdf

Ajanta Pharma Ltd.

31 Jul 2024

2676.40

1.57%

Ajanta Pharma

Buy: Ajanta Pharma Ltd.

Target

ICICI Direct

Promoters pledged 1.44% of shares in last quarter. Total pledge stands at 12.61% of promoter holdings

Ajanta Pharma Ltd.

30 Jul 2024

2676.40

1.57%

Earnings Call

AJANTA PHARMA LTD. - 532331 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

BSE India

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, audio call recording of the earnings call held on 30th July 2024 at 4.30 p.m. has been uploaded on the Company's website and can be accessed through the link: https://ajantapharma.com//images/EarningsAudio-Q1-FY2025.mp3

pdf

Ajanta Pharma Ltd.

30 Jul 2024

2676.40

1.57%

to see Rapid results content

Ajanta Pharma Ltd.

30 Jul 2024

2676.40

1.57%

Company Update

AJANTA PHARMA LTD. - 532331 - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS

BSE India

The Nomination and Remuneration Committee of the Board at its meeting held today allotted 24,325 fully paid up equity shares of Rs. 2 each issued upon exercise of options.

pdf

Ajanta Pharma Ltd.

30 Jul 2024

2676.40

1.57%

Board Meeting

AJANTA PHARMA LTD. - 532331 - Board Meeting Outcome for Outcome Of Board Meeting For Approving …

BSE India

We hereby inform that the Board at the Board meeting held on Tuesday, 30th July 2024, has inter-alia approved the Unaudited (Consolidated & Standalone) Financial Results of the Company for the quarter ended 30th June 2024. PFA enclosed outcome of Board Meeting for more details

pdf

Ajanta Pharma Ltd.

30 Jul 2024

2676.40

1.57%

Result

AJANTA PHARMA LTD. - 532331 - Outcome Of Board Meeting For Approving Unaudited Financial Results For …

BSE India

PFA outcome of Board Meeting

pdf

Ajanta Pharma Ltd.

30 Jul 2024

2676.40

1.57%

Branded generics drive earnings

Buy: Ajanta Pharma Ltd.

Target

Motilal Oswal

Ajanta Pharma (AJP) delivered better-than-expected 1QFY25 performance, led by a superior show in the branded Africa segment, lower raw material costs, and controlled other expenses.

Ajanta Pharma Ltd. has an average target of 2987.67 from 3 brokers.

Ajanta Pharma Ltd.

23 Jul 2024

2676.40

1.57%

Stock Market Live Updates 23 July 2024: Stock to buy today: Ajanta Pharma (2,291.05)

Business Line

Sensex, Nifty, Share Prices LIVE: Ajanta Pharma's stock, which depreciated after marking a record high of 2,531.95 in May, has now formed a good base at 2,200. The price action indicates good buying around these levels and the broader trend is bullish. Therefore, the likelihood of a rally in the forthcoming sessions is high. In the short term, Ajanta Pharma's price can rise to 2,500. But there might be a minor correction, possibly to 2,200, before the next upswing.